The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study

BRAF and MEK inhibition is efficient in patients with BRAF V600-mutated metastatic melanoma, but due to acquired resistance the duration of response (DoR) is often only short-lived. In this retrospective multicenter study with 60 patients suffering from inoperable or metastatic melanoma we evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Tietze, Julia K., Forschner, Andrea, Loquai, Carmen, Mitzel-Rink, Heidrun, Zimmer, Lisa, Meiss, Frank, Rafei-Shamsabadi, David, Utikal, Jochen, Bergmann, Maike, Meier, Friedegund, Kreuzberg, Nicole, Schlaak, Max, Weishaupt, Carsten, Pföhler, Claudia, Ziemer, Mirjana, Fluck, Michael, Rainer, Jessica, Heppt, Markus V., Berking, Carola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188134/
https://www.ncbi.nlm.nih.gov/pubmed/30344946
http://dx.doi.org/10.18632/oncotarget.26149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188134/
https://www.ncbi.nlm.nih.gov/pubmed/30344946
http://dx.doi.org/10.18632/oncotarget.26149

Ejemplares similares